NCT04298021View on ClinicalTrials.gov

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Bile Duct CancerChemotherapy Effect
Interventions
DRUG

AZD6738

"* In AZD6738+Durvalumab cohort~ \- AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks"

DRUG

Durvalumab

Durvalumab 1500 mg iv on D1 Every 4 weeks

DRUG

Olaparib

Olaparib 300 mg bid on D1-28 Every 4 weeks

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04298021 - DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter